Shots:
- CytomX has expanded its collaboration & licensing agreement with Regeneron to develop conditionally-activated bispecific cancer therapies using CytomX’s Probody platform & Regeneron’s Veloci-B BsAb development platform
- As per the expanded deal, the companies will continue joint discovery efforts to identify & validate conditionally active BsAbs, with Regeneron assuming responsibility for all preclinical & clinical development, commercialization, & associated funding
- CytomX will receive $37M for the nomination of 2 additional targets, while Regeneron may select ~6 more future targets. The deal incl. ~$4B in potential nomination, development, regulatory, & commercial milestone payments, plus tiered royalties
Ref: Globenewswire| Image: Regeneron & CytomX | Press Release
Related News: Regeneron Inks a ~$2.3B Deal with Parabilis Medicines to Advance Antibody-Helicon Conjugates Across Multiple Therapeutic Areas
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
